Behavioural Health FDA Approval Medicine 
pharmaphorum
OCTOBER 2, 2020
Modia is designed to close the gap as it relates to the access and receipt of quality, evidence-based therapeutic interventions and behavioural health services for individuals with OUD who participate in outpatient treatment with MAT,” said Michael Sumner, Orexo’s chief medical officer.
pharmaphorum
MARCH 21, 2022
Alongside those organisations sat well-known companies and agencies, such as the National Institute of Health (NIH), Johnson & Johnson, HDMS of CVS Health, Microsoft, Meta, and HP, determined to be part of the fast-growing immersive reality industry. In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co.
Expert insights. Personalized for you.
98 
Let's personalize your content